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CD4BSNeutralizing antibody (nAb) response is sporadic and has limited potency and breadth during infection with
human immunodeﬁciency virus type 1 (HIV-1). In rare cases, broad and potent nAbs are actually induced in
vivo. Identifying speciﬁc epitopes targeted by such broad and potent nAb response is valuable in guiding the
design of a prophylactic vaccine aimed to induce nAb. In this study, we have deﬁned neutralizing epitope
usage in 7 out of 17 subjects with broad and potent nAbs by using targeted mutagenesis in known
neutralizing epitopes of HIV-1 glycoproteins and by using in vitro depletion of serum neutralizing activity by
various recombinant HIV-1 glycoproteins. Consistent with recent reports, the CD4 binding site (CD4BS) is
targeted by nAbs in vivo (4 of the 7 subjects with deﬁned neutralizing epitopes). The new ﬁnding from this
study is that epitopes in the gp120 outer domain are also targeted by nAbs in vivo (5 of the 7 subjects). The
outer domain epitopes include glycan-dependent epitopes (2 subjects), conserved nonlinear epitope in the
V3 region (2 subjects), and a CD4BS epitope composed mainly of the elements in the outer domain (1
subject). Importantly, we found indication for epitope poly-speciﬁcity, a dual usage of the V3 and CD4BS
epitopes, in only one subject. This study provides a more complete proﬁle of epitope usage for broad and
potent nAb responses during HIV-1 infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) infection only in
rare cases induces potent neutralizing antibody (nAb) responses that
can effectively neutralize diverse primary strains of HIV-1 (Deeks et
al., 2006; Dhillon et al., 2007; Li et al., 2007, 2009; Sather et al., 2009;
Shen et al., 2009). Even in such cases, serum neutralizing titers are
often low, with IC50 values in the dilution range of 1:10 to 1:100. The
nature of such broad and potent nAbs to HIV-1 envelope glycoproteins
(Envs) is of interest for vaccine development, as passive immuniza-
tion with broad and potent nAbs can prevent virus infection in the
rhesus macaque model of SHIV infection (Mascola et al., 1999; Parren
et al., 2001; Shibata et al., 1999; Veazey et al., 2003). The existence of
nAbs with high neutralizing potency and breadth in vivo has beeng).
ll rights reserved.demonstrated by the characterization of monoclonal antibodies
(mAbs) 2G12, 2F5, and 4E10, generated by hybridoma formation or
EBV transformation of B lymphocytes (Muster et al., 1993; Stiegler et
al., 2001; Trkola et al., 1996; Zwick et al., 2001). Of note, the broad and
potent neutralizing mAb-b12 was produced using recombinant phage
technology, whereas mAbs PG9 and PG16 were produced using
recombinant techniques based on near-clonal B-cell cultures (Burton
et al., 1994; Walker et al., 2009). Many mAbs either have limited
potency but relatively good breadth or have high potency but are
strain-speciﬁc in neutralization (reviewed in Wyatt and Sodroski,
1998; Zolla-Pazner, 2005). Hypothetically, broad and potent nAb
responses in vivo may also be composed of a high concentration of
antibodies with limited potency/good breadth or a large number of
antibodies with limited breadth/high potency, or some combination
of these extremes.
HIV-1 Envs exist on the virion surface as a trimer of gp120/
gp41 heterodimers, representing the only viral target for Env-
340 A. Nandi et al. / Virology 396 (2010) 339–348speciﬁc nAbs. Primary sequences of HIV-1 gp120 have ﬁve
conserved (C1–C5) and ﬁve variable (V1–V5) regions, and the
gp41 ectodomain is well-conserved among HIV-1 variants (Gaschen
et al., 2001; Kuiken, Korber, and Shafer, 2003; Modrow et al., 1987;
Myers et al., 1992; Starcich et al., 1986; Willey et al., 1986). The
gp120 variable regions are exposed on the mature Env trimer and
are heavily glycosylated, protecting the conserved gp120 structures
from nAbs (Modrow et al., 1987; Starcich et al., 1986; Wyatt et al.,
1998). Most known broad nAbs to HIV-1 Envs target epitopes in
ﬁve structural regions. (1) The CD4BS is the binding target for b12,
a broad and potent nAb, as well as some broad but less-potent
nAbs, such as F105, F91 and 1.5e (Burton et al., 1994; Moore et al.,
1994; Posner et al., 1993; Robinson et al., 1990). Typical CD4BS
epitopes lie between the inner and outer domains of gp120, thus
comprising elements of both domains. Both recombinant gp120
monomer and gp140 trimer contain such epitopes (Yang et al.,
2000b, 2002). Interestingly, the b12 epitope is largely made of
elements from gp120 outer domain and is capable of binding the
recombinant form of gp120 outer domain known as OD1, in
addition to gp120 and gp140 (Yang et al., 2004; Zhou et al., 2007).
(2) The CD4-induced (CD4i) site is the gp120 core structure
binding to the coreceptor, either CCR5 or CXCR4 (Moore and
Sodroski, 1996; Thali et al., 1993; Xiang et al., 2003). It is poorly
exposed before CD4 engagement and virus attachment, thus is a
poor target for nAbs (Decker et al., 2005; Li et al., 2006). The V3
loop is adjacent to this site and contributes signiﬁcantly to
coreceptor binding. V3-speciﬁc nAbs are mostly strain-speciﬁc,
but a few anti-V3 antibodies have also been described to have
somewhat greater neutralizing breadth (Gorny et al., 1997, 2002;
Stanﬁeld et al., 2004). The V3 region is a part of the gp120 outer
domain. The OD1 protein, but not its V3-deleted version (ODΔV3),
can bind V3-speciﬁc antibodies that are conformation-dependent
and neutralizing but not those that target the linear V3 sequences
and are nonneutralizing (Yang et al., 2004). (3) 2G12 is the only
nAb targeting the glycan mass on the surface of gp120 outer
domain, known as the “silent face” (Trkola et al., 1996). 2G12
efﬁciently binds to recombinant HIV-1 glycoproteins including
gp140 trimer, gp120 monomer, and OD1. (4) The V2 loop is
recently identiﬁed as the target for mAbs PG9 and PG16 which
neutralize almost all group M HIV-1 strains with great strength
(Walker et al., 2009). The epitope for PG16 also involves the V3Table 1
Neutralization titers of sera from selected subjects against Tier-2 HIV-1 strains.a
Subjects Clade B, Tier-2b C
B1 B2 B3 B4 B5 B6 C
C1-211c 251 518 58 679 396 748 1
C1-210 245 315 157 114 257 34 2
C1-343 1827 245 287 1000 156 593
C1-540 151 58 184 1158 22 514
C1-581 263 39 284 1690 154 735
C1-090 235 44 34 120 224 397
C1-111 124 109 1776 299 458 64
C1-141 216 188 544 141 77 94
C1-259 718 254 161 315 147 83
C1-440 441 288 759 399 155 230 1
C8-117 44 190 508 97 118 103
C8-258 262 196 371 242 57 180
C1-328d 68 42 b20 134 68 72
UAB-B 721 157 224 123 315 160
UAB-M 525 255 756 1568 93 367
UAB-Dd 83 105 349 845 69 121
UAB-Sd 163 195 106 263 30 79
a All IC50 values were obtained once and reported as it is.
b HIV-1 strains: B1-B6 are 6535, QH0692.42, SO422661.8, RHPA4259.7, AC10.0.29, and P
CAP45.2.x.
c Subjects' name with “C1-xxx,” “C8-XXX,” and “UAB-x” were from cohorts CHAVI001, C
d Subjects not ﬁtting the selection standards, i.e., with more than two IC50 values belowstructure. (5) The membrane proximal external region (MPER) of
the gp41 ectodomain contains two well-characterized neutralizing
epitopes—2F5 and 4E10 (Muster et al., 1993; Zwick et al., 2001).
The gp140 trimer contains the sequences covering these epitopes,
but not the gp120 monomer (Yang et al., 2002). Interestingly, the
gp120 outer domain contributes major binding surfaces for the ﬁrst
3 groups of nAbs, making it a high-density target for nAb responses
(Kwong et al., 1998; Yang et al., 2004; Zhou et al., 2007).
Recent efforts have demonstrated the use of CD4BS in a few
individuals in vivo by using recombinant HIV-1 gp120 and its epitope-
speciﬁc mutant derivatives to bind and deplete nAbs from antisera
containing broad and potent nAbs (Binley et al., 2008; Dhillon et al.,
2007; Gray et al., 2009b; Li et al., 2007, 2009; Sather et al., 2009). The
gp41 MPER epitopes have also been reported as targets of nAbs with
various neutralizing breadth and potency (Gray et al., 2009a, 2009b;
Shen et al., 2009). In this report, we have characterized nAb responses
in chronic HIV-1 infections using a panel of HIV-1 Env mutants to
detect the change of sensitivity to neutralization due to alterations in
known immunoepitopes. Complemented by the commonly used
technique of depleting neutralizing activities from antiserum using
recombinant HIV-1 Env proteins, we found that in addition to the
CD4BS site, epitopes located in the gp120 outer domain, including
glycan-dependent epitopes and conserved elements of the V3 region,
are also targeted by broad and potent nAbs developed in chronic HIV-
1 infection.
Results
Neutralizing antibody responses in people with chronic HIV-1 infection
We collected serum or plasma samples from 244 subjects with
chronic HIV-1 infection in 3 separate cohorts with diverse genetic
backgrounds. Neutralizing activity in samples was titrated against a
panel of tier-2 HIV-1 strains (6 each from clades B and C) by a
neutralization assay based on the single-round entry of pseudotyped
viruses into the TZM-bl luciferase reporter cells as described (Li et al.,
2006). Samples from 14 (≈6%) of 244 subjects neutralized 10 of the
12 tier-2 HIV-1 strains with an IC50 of 1:100 dilution or higher
(Table 1). For our study, this level of neutralizing activity was deﬁned
as “broad and potent nAb responses in vivo.” These 14 samples did not
inhibit the entry of SVA-MLV, indicating that the virus-inhibitinglade C, Tier 2 SVA-MLV
1 C2 C3 C4 C5 C6
059 288 244 1175 b20 228 b20
802 378 102 1692 971 138 b20
206 238 362 195 48 54 b20
220 163 178 122 305 1262 b20
349 1349 250 136 704 173 b20
192 209 3414 136 150 2522 b20
119 120 150 191 132 676 b20
250 167 86 234 152 521 b20
882 486 184 314 249 938 b20
480 282 190 312 191 369 b20
662 163 209 327 b20 295 b20
289 123 356 567 625 640 b20
143 88 b20 371 b20 82 b20
106 208 183 44 116 51 22
169 68 77 355 248 99 b20
372 35 95 206 362 330 b20
50 64 96 87 56 29 b20
VO.4, and C1-C6 are Du156.12, Du172.17, Du422.1, ZM197M.PB7, ZM214M.PL15, and
HAVI008, and UAB, respectively.
1:100.
Fig. 1. Use of the glycan-dependent epitopes on the gp120 outer domain. To quantify
and compare the neutralization sensitivity of the wild-type and N332S HIV-1JR-FL
gp160s to mAb 2G12 and subject antisera, the residual infectivity was measured using
the single-round entry/neutralization assay. The luciferase activity of the mock-treated
virus was used as the index of total infectivity, set as 100%, to which the infectivity of
antibody-treated viruses was standardized as a percentage. The wild-type and N332S
mutant Envs were neutralized by mAb 2G12 (A), antiserum C1-343 (B), and antiserum
C1-259 (C). The same molar amounts of gp140 trimer (40 μg), gp120 monomer
(13.3 μg), and OD1 (5 μg) were used to deplete neutralizing activity from antisera C1-
343 (D) and C1-259 (E). The same amount of bare Ni-NTA Superﬂow beads (Qiagen),
designated as “No Nickel,” was used as negative control.
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anti-HIV-1 drugs as consistent with the subjects' self-reporting. The
protein-A-binding immunoglobulins from these samples exhibited
similar levels of neutralization against a subgroup of the 12-virus
panel, indicating that the neutralizing activity was truly attributable
to neutralizing antibodies (data not shown). The samples from these
14 patients were further investigated to dissect the neutralizing
epitope usage in vivo during chronic HIV-1 infection.
Three additional subjects, marked with superscript letter “d” in
Table 1, had neutralizing activities that did not fulﬁll our deﬁnition of
“broad and potent nAb responses” described above but were also
included in the analysis of neutralizing epitope usage in vivo. The
samples of subjects UAB-S and UAB-D exhibited rather potent
neutralization of HIV-1 strains of JR-FL, KB9, ADA, YU2, and HXBc2
in our initial screening (data not shown), thus being of interest for
further study. The C1-328 sample exhibited potent inhibition of a few
target viruses with especially high titers due to an experimental error;
the neutralizing titers were subsequently re-measured in repeated
experiments and reported in Table 1. Although the neutralizing titers
of C1-328 did not meet the selection standards set for this study, the
neutralizing epitope targeted in this sample was easily identiﬁed and
thus is included in this report.
Usage of the glycan-dependent epitopes in the gp120 outer domain
The gp120 outer domain is heavily glycosylated. Multiple N-linked
glycans in the gp120 “silent face” form a neutralizing epitope
recognized by mAb 2G12 (Sanders et al., 2002; Scanlan et al., 2002;
Trkola et al., 1996). Removal of a glycan by the N332Smutation results
in neutralization escape from 2G12 in several strains of HIV-1 Envs
(Yang et al., 2005). As expected, the N332Smutant of HIV-1JR-FL gp160
was neutralized by 2G12with low efﬁciency compared to the parental
Envs (Fig. 1A). The N332S mutant escaped neutralization by the C1-
343 and C1-259 sera for more than two 1:2 dilutions compared with
the parental Envs (Figs. 1B and 1C). For this study, a reduction of
neutralization titer by two 1:2 dilutions was deﬁned as a signiﬁcant
difference, indicating that the N332S mutant had a demonstrable
escape from the neutralizing activity in the sample. Experimentally,
this level of change in neutralizing titer is used as an indication that the
majority of the neutralizing activity in that sample is targeted to the
speciﬁc epitope. Moreover, the levels of neutralization escape by the
N332Smutation fromsamples C1-343 and C1-259were comparable to
that of puriﬁed 2G12, suggesting that the nAbs targeting the epitopes
involving in the N332 residue accounted for most of the neutralizing
activity in these antisera. The neutralizing activities of C1-343 and C1-
259 were dependent on the N332 residue which is glycosylated and is
an integral part of the glycan-dependent epitope of 2G12 (Trkola et al.,
1996). Samples from other subjects did not neutralize the wild-type
and N332S Envs differently (data not shown). The recombinant OD1
protein contains a functional epitope of 2G12 and can be precipitated
by 2G12 (Yang et al., 2004). Surprisingly, the neutralizing activities in
C1-343 andC1-259were not depleted by theOD1protein (Figs. 1D and
1E). Finally, the neutralizing activity in C1-343 but not C1-259 was
effectively depleted by recombinant gp120 monomer and gp140
trimer (Figs. 1D and 1E). Together, these data indicate that glycan-
dependent epitopes in the gp120 outer domain are targeted by
antisera C1-343 and C1-259 and that the internal compositions of the
two epitopes differ from each other and also from the glycan
composition of the 2G12 epitope. In addition, to test whether the
N332 glycan is the direct and main binding target by nAbs in the C1-
343 and C1-259 antisera, we attempted to remove the glycan from
virion-associated glycoproteins using glycosidases. However, even
using a large panel of glycosidases, we could not achieve a level of de-
glycosylation that selectively modiﬁes neutralizing efﬁciency by mAb
2G12 and antisera C1-343 and C1-259, without inactivating the viral
infectivity (data not shown).Usage of other epitopes in the gp120 outer domain
The outer domain of gp120 contains most of the neutralizing
epitopes against HIV-1 gp120 (Kwong et al., 1998). OD1 is a
recombinant form of the gp120 outer domain, containing amino
acids 252 to 482 (Yang et al., 2004; Zhou et al., 2007). OD1 binds mAb
2G12 as well as many conformation-dependent anti-V3 mAbs
efﬁciently but not to those antibodies targeting linear sequences
(Yang et al., 2004). OD1 binds mAb b12 weakly with an afﬁnity
detectable only by surface plasmon resonance but not by immuno-
precipitation (Yang et al., 2004; Zhou et al., 2007). The protein was
expressed in insect cells and puriﬁed to homogeneity, as reported
previously (Yang et al., 2004). Using a vigorous depletion protocol,
OD1 depleted neutralizing activity from antisera C1-211, C1-540, and
UAB-D, indicating that the epitopes present on OD1 are targeted by
nAbs in these subjects (Fig. 2A).
Fig. 2. Use of other neutralizing epitopes on the gp120 outer domain. (A) Five micrograms of either OD1 or OD1ΔV3 proteins was used to deplete nAbs from subject antisera. Owing
to variation in different experimental sessions, the data on UAB-D represent averages of 4 independent experiments. (B) The neutralizing activity that survived the competition with
10 μg/ml of the HIV-1JR-FL V3 peptide was measured using the standard neutralization assay, compared with same antiserummock-treated with culture medium. The same quantity
of peptide was also used to treat the target virus in parallel and demonstrated no detectable inhibition of virus infectivity (data not shown).
Fig. 3. Serum-neutralizing activity from subject C1-328 is sensitive to a change in the
CD4BS region. Luciferase reporter viruses carrying the wild-type or T257A HIV-1JR-FL
gp160s were subjected to neutralization by b12 (A) or antiserum C1-328 (B).
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deleting amino acids 299 to 328 (Yang et al., 2004). The OD1ΔV3
protein did not deplete neutralizing activity from the C1-540 serum.
Also, the C1-540 neutralizing activity was not blocked by a V3 peptide
in a binding/competition assay (Fig. 2B). Together, these data suggest
that a conserved V3 structure, but not a linear V3 sequence, was
targeted for neutralization by antiserum C1-540. The neutralizing
activity in UAB-D was not depleted by OD1ΔV3 but by OD1 at a level
of one to two 1:2 dilutions (Fig. 2A). The level of depletion by OD1was
modest but reproducible, consistent with the presence of nAbs with
speciﬁcity for a conserved V3 structure in this antiserum; further
studies revealed the presence of nAbs in this antiserum with
additional speciﬁcity (see below in Fig. 4). The neutralizing activity
of UAB-D was not blocked by a V3 peptide in a competition assay
(Fig. 2B). In addition, the V3 peptide did not competitively block the
neutralizing activity in any of the 17 samples, indicating that linear
epitopes within the gp120 V3 loop do not serve as targets for broad
and potent nAb responses in these subjects (data not shown).
The neutralization activity in C1-211 was depleted by both
recombinant OD1 and OD1ΔV3, indicating that the targeted epitope
is located within the main body of the gp120 outer domain (Fig. 2A).
Data from additional experiments suggest that the epitope targeted
by this antiserum involves the CD4BS region (see below in the CD4BS
section).
Detection of epitope use in the CD4BS region by the T257A mutant gp160
CD4 binds to the gp120 surface formed by elements of the outer
domain and the bridging sheet (Kwong et al., 1998). This region,
known as CD4BS, contains many neutralizing epitopes, targeted by
the recombinant mAb b12 that is broadly and potently neutralizing
(Burton et al., 1994). We investigated the potential usage of a b12-like
epitope by the subjects' antisera with a large panel of mutant gp160
variants, including P369L/D167N/D185N, N276A, A281V, S365A,D368Q, P369M, I371V, V372T, M373R, and K432S. Owing to the
heavy overlap between the CD4-binding surface and the b12 epitope,
most of thesemutants had signiﬁcant defects in entry function and/or
no escape from b12 neutralization; and additionally, neutralizing
activity in none of the subject samples neutralized the wild type
gp160 and these mutant variants with discernible difference in
efﬁciency (data not shown). The T257 residue has direct contact via its
main peptide chain and side chain with b12 and it has no direct
contact with the CD4 molecule, although it abuts the Phe43 cavity
(Zhou et al., 2007). The T257A mutant exhibited no detectable escape
from b12 neutralization (Fig. 3A). When tested against the 17
samples, the T257A virus was neutralized by serum C1-328 with a
titer reduction of over two 1:2 dilutions compared to the wild-type
virus, suggesting that the T257 residue was involved in the
neutralizing epitope targeted by this antiserum (Fig. 3B). The T257A
Fig. 4. Detection of CD4BS nAbs using depletion by recombinant Env proteins. (A) The wild-type and D368R mutant HIV-1JR-FL gp120 monomer and the gp140(-/FT) trimer were
expressed in 293F cells and puriﬁed by Ni-NTA afﬁnity column. Ten micrograms of the ﬁnal product was analyzed on an 8% SDS–PAGE gel under reducing and nonreducing
conditions and visualized by Coomassie blue staining. (B) Same molar amounts of the wild-type or D368R gp120 monomer or the gp140 trimer were used to deplete neutralizing
activity from subject antisera. The neutralizing activity in the ﬁnal ﬂow-through was measured using the standard neutralization assay, in parallel to the same antiserum mock-
depleted by empty Ni-NTA beads. Owing to variations in different experimental sessions, the data on UAB-D represent averages of 4 independent experiments.
343A. Nandi et al. / Virology 396 (2010) 339–348and wild-type viruses were neutralized equally by serum C1-343 and
the other subject antisera (data not shown). The S375W change
introduces an indole ring in the Phe43 cavity (Kwong et al., 1998;
Xiang et al., 2002; Zhou et al., 2007). This mutation reduces gp120
binding to CD4BS antibodies, including b12, F105, and 1.5e (Xiang et
al., 2002). The S375W virus was indistinguishable from the wild-type
virus when subjected to antiserum C1-328 (Fig. 3B). Strikingly, the
neutralizing activity in C1-328 was not depleted by the gp120
monomer or the gp140 trimer (Fig. 4B), although both of these
recombinant HIV-1 Env preparations are known to bind mAb b12 and
other CD4BS mAbs (Yang et al., 2000a, 2000b). Together, these data
support the notion that antiserum C1-328 contains a CD4BS-speciﬁc
nAb(s) that is distinguishable from other known anti-CD4BS nAbs,
including b12.Detection of epitope use in the CD4BS region by depletion with
recombinant Env proteins
The D368R mutation in recombinant gp120 results in a loss of the
ability to bind and deplete antibodies directed against the CD4BS site
(Li et al., 2007; Thali et al., 1992). This phenotype change has been
utilized to characterize the presence of the CD4BS nAbs in patient sera
by several groups (Binley et al., 2008; Dhillon et al., 2007; Gray et al.,
2009b; Li et al., 2007, 2009; Sather et al., 2009). We adopted this assay
to complement the experiments described above. The recombinant
gp120 monomers of wild-type and D368R HIV-1JR-FL Envs were
expressed in 293F suspension cells and puriﬁed to homogeneity (Fig.
4A). Using very vigorous depletion conditions, wild-type gp120
depleted signiﬁcant levels of neutralizing activity from UAB-M, C1-
Table 2
Summary of epitopes for broad and potent nAbs in HIV-1-infected persons.
Subject ID Speciﬁc escape Depletion Epitope projection
OD1 OD1ΔV3 gp120 gp120.D368R gp140
C1-343 N332S No n/da Yes n/d Yes OD glycan
C1-259 N332S No n/d No n/d No OD glycan
C1-540 None Yes No Yes n/d Yes OD V3
UAB-D None Yes No Yes No Yes OD V3/CD4BS
C1-211 None Yes Yes Yes No Yes OD CD4BS
UAB-M None No n/d Yes No yes CD4BS
C1-328 T257A No n/d No n/d No CD4BS
UAB-S None No n/d Yes Yes Yes Not identiﬁed
C1-210 None No n/d No No No Not identiﬁed
C1-111 None No n/d No No No Not identiﬁed
C1-141 None No n/d No No No Not identiﬁed
C8-117 None No n/d No No No Not identiﬁed
UAB-B None No n/d No n/d No Not identiﬁed
C8-258 None No n/d No No No Not identiﬁed
C1-440 None No n/d No No No Not identiﬁed
C1-090 None No n/d No No No Not identiﬁed
C1-581 None No n/d No No No Not identiﬁed
a: n/d=not done.
344 A. Nandi et al. / Virology 396 (2010) 339–348211, UAB-D, and UAB-S (Fig. 4B). In contrast, wild-type gp120 did not
appreciably deplete neutralizing activity in 11 other samples
(Table 2), notably antiserum C1-328 which has nAb(s) to an epitope
involving residue T257 (see above; Fig. 4B and data not shown). The
neutralizing activity was depleted by both the wild-type and D368R
gp120 monomers, suggesting that the targeted neutralizing epitope is
located outside the CD4BS region (Fig. 4B). The neutralizing activity in
UAB-M was depleted by the wild-type gp120 but not by the D368R
variant, similar tomany known CD4BS nAbs (Fig. 4B). The neutralizing
activity of C1-211 was depleted efﬁciently by the wild-type but not
D368R gp120, suggesting that the CD4BS site was targeted by this
antiserum (Fig. 4B). As shown in Fig. 2, the neutralizing epitope
targeted by antiserum C1-211 is located in themain body of the gp120
outer domain. Taken together, these results support the notion that
the nAb(s) in antiserum C1-211 targets a CD4BS epitope that is
mainly, if not exclusively, composed of elements from the gp120 outer
domain.
The neutralizing activity in antiserum UAB-D was depleted by the
wild-type gp120 at a level between one to two 1:2 dilutions in
repeated experiments, and this neutralizing activity was not depleted
by the D368R gp120 (Fig. 4B). These data indicated the presence of a
CD4BS nAb in this serum, although this level of depletion is below
what we deﬁne as a signiﬁcant difference in this study. As shown in
Fig. 2, this antiserum also contains neutralization activity speciﬁc for a
conserved V3 structure (see above). The simplest rational explanation
for the combined data in Fig. 4B and Fig. 2 is that the neutralizing
activity in UAB-D comprises two speciﬁcities, one for CD4BS and one
for the conserved V3 structure.
Summary of the neutralizing epitope use during chronic HIV-1 infection
Table 2 summarizes the neutralizing epitope usage for the 17
subjects with chronic HIV-1 infection from diverse backgrounds. The
most frequently used epitopes (4/17) is in the CD4BS region. There
are three epitopes in the gp120 outer domain targeted for neutral-
ization in 5 subjects. Among the epitopes residing in the gp120 outer
domain, two are the N332S-sensitive, glycan-dependent epitopes on
the silent face of gp120, two are composed of conserved V3 structural
elements, and one is a CD4BS epitope. Neutralizing epitope usage in
10 of the 17 subjects is refractory to characterization by the two
methods used in this study. Among these 10 subjects, 9 have
neutralizing activity that is not sensitive to depletion by recombinant
HIV-1 Env proteins, including OD1, gp120, gp140 trimer, and their
derivatives. The failure to deplete neutralizing activity from most of
the HIV-1-neutralizing antisera by similar recombinant HIV-1proteins has been reported by multiple investigators, indicating
signiﬁcant differences in the structure of these recombinant proteins
from that of a native, functional Env trimer presented on virion
surface (Table 2) (Binley et al., 2008; Dhillon et al., 2007; Gray et al.,
2009b; Li et al., 2007, 2009; Sather et al., 2009).
Discussion
We studied 244 subjects with chronic HIV-1 infection from 3
cohorts with diverse backgrounds. Approximately 6% of the subjects
(14 out of 244 subjects) has broad and potent nAb responses that can
neutralize 80% of tier-2 HIV-1 strains with a serum dilution titer of
1:100 or higher. This frequency of responses of broad and potent
neutralizing antibodies during HIV-1 infection is consistentwith other
ﬁndings (Binley et al., 2008; Li et al., 2009; Simek et al., 2009). In
samples from the 17 subjects, the CD4-binding site is targeted for nAb
responses in vivo in 4 cases, consistent with recent ﬁndings (Binley et
al., 2008; Dhillon et al., 2007; Gray et al., 2009b; Li et al., 2007, 2009;
Sather et al., 2009). The novel result from our study is that the gp120
outer domain is also frequently targeted (5 of the 17 subjects) by
naturally arising nAbs in vivo. The neutralizing epitopes in the gp120
outer domain can be classiﬁed into three groups: (1) the CD4BS
epitopes (n=1), (2) glycan-dependent epitopes (n=2), and (3) the
conserved V3 structures (n=2). Using a synthetic peptide homolo-
gous to the target HIV-1JR-FL V3 loop to compete/block for V3-speciﬁc
antibodies (see Materials and methods), we detected no neutralizing
activity targeting the gp120 V3 linear peptide sequences in this group
of 17 subjects. Using a K665N/W672mutant to screen for neutralizing
activity to the 2F5 and 4E10 epitopes (data not shown), no
neutralizing activity targeting the 2F5/4E10 epitopes of MPER was
found in the 17 subjects. However, limited experiments in this study
cannot rule out nAbs to these epitopes may contribute to the
neutralizing activity in some of the subjects. We have not yet
attempted to detect the potential use of the V2/V3 epitopes targeted
by mAbs PG9 and PG16 in this study.
In our experiments, the identiﬁcation of targeted neutralizing
epitopes is based on the detection of a change of neutralization
efﬁciency by two or more 1:2 dilutions of an antiserum. In most cases
(6 of the 7 subjects with deﬁned epitope usage), the neutralizing
epitope identiﬁed by this experiment standard is responsible for the
majority of the neutralizing activity in the antiserum. The neutralizing
activity in the antiserum UAB-D is sensitive to deletion of the V3 loop
(depletion by the OD1 and OD1ΔV3 proteins) and also to the D368R
mutation (in the context of depletion by the gp120 and gp120.D368R
monomers). It is not clear why the V3 loop in the gp120.D368R
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sensitive to depletion by OD1 but not OD1ΔV3; it may be that the V3
loop is simply exposed better in OD1 than in gp120 monomer, thus
leading to better binding of OD1 and the targeted nAbs. Notwith-
standing this possibility, poly-speciﬁcity of nAbs in subject UAB-D for
both V3 and CD4BS epitopes is the most logical explanation for the
differential depletion of neutralizing activity by OD1/OD1ΔV3 and
gp120/gp120.D368R and for the observation that both gp120 and
OD1 can only achieve a partial depletion of neutralizing activity,
relative to that achieved for other antisera with apparently mono-
speciﬁc neutralizing epitope usage (Figs. 2A and 4B). It is possible that
the D368R mutation can affect antibody binding by the V3 loop in the
context of monomeric gp120; and the UAB-D antiserum is speciﬁc for
the V3 epitope only. However, based on current understanding of the
structure of HIV-1 gp120, such an effect of the D368R change would
not be expected (Chen et al., 2005; Kwong et al., 1998, 2000; Liu et al.,
2008; Zhu et al., 2003).
Our data indicate that glycan-dependent epitopes in the gp120
outer domain, related to the 2G12 epitope, are targeted in 2 of the 17
subjects, although binding of the glycan itself has not been proven
directly. This adds to the evidence that the glycans concentrated on
the gp120 outer domain can induce nAb responses in vivo, as
indicated by the isolation of mAb 2G12 using the technology of EBV
transformation of B lymphocytes from an HIV-1-infected individual
(Trkola et al., 1996). In our study, we used a single glycan-deleting
mutant, thus potentially underestimating the frequency at which this
type of nAb is induced during HIV-1 infection. The composition of
such glycan-dependent epitopes might be diverse. For example, both
the gp120 and the gp140 trimer can deplete the neutralizing activity
from the C1-343 antiserum but not from the C1-259 antiserum. In
addition, OD1 does not deplete the neutralizing activities from
antisera C1-259 and C1-343, despite OD1 being able to efﬁciently
bind to 2G12 (Yang et al., 2004). The diversity in glycan compositions
of this epitope group may make the design of immunogens to induce
similar nAb responses challenging, consistent with the outcome of a
recent study (Luallen et al., 2008).
Two of the 17 subjects, C1-540 and C1-211, have nAbs targeting
the conserved structural elements of V3, while none have nAbs to the
linear peptide epitopes in V3. The V3 tip, especially those with the –
GPGR– sequence, has been reported to bind potent and broad nAb in
vitro (Gorny et al., 1993; Stanﬁeld et al., 2004). However, while the
multi-speciﬁcities of the nAbs in the C1-211 antiserum complicate the
assessment of the neutralization breadth of the V3-speciﬁc nAbs in
this antiserum, the neutralization breadth of the anti-V3 nAb in C1-
540 is signiﬁcantly wider than that of the anti-V3 antibodies reported
previously (Gorny et al., 1993; Stanﬁeld et al., 2004). The V3 base is
also conserved structurally as shown in several X-ray crystal
structures and in primary sequences (Kwong et al., 1998, 2000).
Although the exact nature of these V3 epitopes is not clear, they
represent novel neutralizing targets worthy of further investigation.
Among the known neutralizing epitopes, the CD4BS region are
targeted frequently by broad and potent nAbs in vivo while the
frequency is very low among the general population of HIV-1-infected
people, consistent with recent reports (Dhillon et al., 2007; Gray et al.,
2009b; Li et al., 2007, 2009; Sather et al., 2009). This conclusion is also
generally consistent with early reports of serum nAb speciﬁcities
based on studying TCLA strains of HIV-1 (Haigwood et al., 1992; Kang
et al., 1991; Moore and Ho, 1993). The CD4BS-speciﬁc nAbs in subjects
UAB-D and UAB-M exhibit known characteristics commonly associ-
ated with CD4BS antibodies, such as not binding to gp120.D268R
(Table 2) and sensitivity to some mutations that affect the structural
integrity of HIV-1 glycoprotein (data not shown). The CD4BS-speciﬁc
nAbs in subjects C1-211 and C1-328 have distinct characteristics. The
C1-211 epitope resides largely, if not totally, in the gp120 outer
domain, as the neutralizing activity of this antiserum was efﬁciently
depleted by the OD1 protein. It has been suggested that thepropensity to bind a larger part of the outer domain as its epitope
contributes to the neutralization effectiveness of mAb b12, compared
to other CD4BS antibodies that have less neutralizing capacity
(Pantophlet et al., 2003; Saphire et al., 2001; Zhou et al., 2007).
Thus, ﬁne dissection of the antibody and the epitope in C1-211 might
provide important clues for redesigning the OD1 protein to improve
its immunogenicity (Wu et al., 2009; Yang et al., 2004). The epitope
targeted in C1-328 is located within the CD4BS region as indicated by
its sensitivity to the T275A mutation. Distinct from known CD4BS
mAbs such as b12, F107, and F91, this neutralizing activity is not
sensitive to the S375W mutation and is resistant to depletion by
recombinant gp120 and gp140 trimers (Figs. 3B and 4B). Thus, the
nAb(s) in this antiserum appears to have a distinct ability to recognize
the native, infectious HIV-1 Env trimers but not the recombinant Env
proteins. The inability of recombinant gp120 and gp140 trimer to
deplete neutralizing activities from antisera in this study as well as in
many other reports is indicative of the structural defect in these
recombinant HIV-1 Env proteins when compared to a native HIV-1
Env trimer. The structure of a native, infectious HIV-1 Env trimer is
still an illusive entity in the ﬁeld, and clear understanding of it is
critical for modiﬁcation of recombinant Env proteins as vaccine
candidates. Thus, characterizing the nAb(s) in antiserum C1-328 and
deﬁning the neutralizing epitope clearly will be helpful to deﬁne the
properties of an HIV-1 Env trimer in its native state.
Finally, we showed that 11 of 17 subjects have nAbs which cannot
be depleted by any of the recombinant Env proteins. Differential
depletion using the wild-type and D368R mutant gp120s only
contributed to the characterization of 2 antisera in this study, similar
to several recent studies (Binley et al., 2008; Dhillon et al., 2007; Li et
al., 2007, 2009; Sather et al., 2009). In this study, we have developed
some new approaches to identify the epitope usage in vivo by
studying serum neutralizing activity. However, it is clearly that there
is still an urgent need to further develop new and more effective
methods to deﬁne the neutralizing epitope usage in HIV-1 infection.
Materials and methods
Patient populations
The subjects came from three independent groups of patients
chronically infected with HIV-1. The ﬁrst group was from clinical
centers located in Africa and the United States, managed by the Center
for HIV/AIDS Vaccine Immunology (CHAVI) as the CHAVI001 study
cohort. This group included adults based on standard clinical
diagnosis of HIV-1 infection with no past or current usage of
HAART. The second group included patients cared for by the King's
College Hospital, London, UK, and the MRC Laboratories, Fajara,
Gambia. Patients from the King's College Hospital comprised a large
proportion of immigrants from Africa. These patients were diagnosed
with standard clinical tests for at least 6 months and had no history of
HAART or had stopped all antiretroviral therapy for at least 3 months.
The third group included patients at the University of Alabama
Medical Center, Birmingham, Alabama. These patients were diag-
nosed by standard clinical tests with conﬁrmation by the detection of
HIV-1 vRNA. These subjects were selected to (1) have documented
HIV-1 infection for more than 1 year, (2) have no history of HAART or
to have stopped all antiretroviral therapy for at least 3 months, and
(3) have lower viral load (b11,000 vRNA/ml plasma) without
therapy. In summary, our study subjects were of diverse background
and were chronically infected with HIV-1 but not treated with HAART
at the time of sampling.
Titration of HIV-1-neutralizing activity in plasma or serum samples
All plasma and serum samples were ﬁrst incubated at 56 °C for
30 min to inactivate complements. Neutralization titers were
346 A. Nandi et al. / Virology 396 (2010) 339–348determined against a standard panel of tier-2 reference strains of HIV-
1 including 6 each from clades B and C, performed according to
standard operating procedure in the laboratory of Dr. D. Monteﬁori
(Duke Human Vaccine Institute, Duke University Medical Center) (Li
et al., 2005). The pseudotyped HIV-1 reporter viruses were studied in
a single-round entry format using the TZM-bl target cells. A speciﬁcity
control of HIV-1 reporter virus carrying the glycoprotein of ampho-
tropic murine leukemia virus (SVA-MLV) was included in each
experiment. The IC50 value for each combination of serum/plasma
sample and target strain of HIV-1 was generated using standard
methods. For subjects whose samples were used for epitope mapping,
neutralization titers were reconﬁrmed by independent experiments
using another form of neutralization assay, as described below.
Reporter virus stocks, single-round infection assay and neutralization
assay
Wild-type and mutant HIV-1JR-FL gp160 glycoproteins were
expressed from the pSVIIIenv vector (Sullivan et al., 1998). Mutants
were created by the PCR-based QuikChange protocol (Stratagene).
The integrity of constructionwas conﬁrmed by DNA sequencing of the
entire env reading frame. The names of the mutants designate the
wild-type amino acid residue in single-letter code, the residue
number, and the substituted amino acid. Residue numbering is
based on that of the prototypic HIV-1HXBc2 gp160, according to current
convention (Korber et al., 1998).
Recombinant HIV-1 encoding ﬁreﬂy luciferase and pseudotyped
with the wild-type or mutant Envs was produced as previously
described (Yang, Wyatt, and Sodroski, 2001). Brieﬂy, 293T cells in
100-mm tissue culture dishes were cotransfected using the Effectene
reagent (Qiagen) with 1 μg pSVIIIenv plasmid expressing the Env
variants and 4 μg of the pNL4-3Δenv.luc vector. The pNL4-3Δenv.luc
vector contains a luciferase reporter gene in the HIV-1 nef locus and
all HIV-1 genes except env and nef (Connor et al., 1995). The viral
stocks were harvested 2 days later, aliquoted and stored at−80 °C. All
viral stocks to be compared directly were prepared as a set.
The infectivity of recombinant viruses was measured by incuba-
tion of the viruses with the Cf2Th-CD4/CCR5 target cells in a 96-well
format. Viral stocks were serially diluted in a total volume of 400 μl.
After thoroughly removing the media from the target cells, 100 μl of
the diluted virus suspension were added to each well in triplicates.
After 48 hours, viral infectivity was quantiﬁed as the luciferase activity
measured by a luciferase detection kit (Pharmingen) and an
automated luminometer (Berthod). The mean value and range of
variation of luciferase activity from the triplicate wells were used for
further analysis.
For the neutralization assays, serial dilutions of the neutralizing
agent, i.e., antiserum/plasma or mAb, were made in medium in such a
volume as to produce the designated ﬁnal concentration after the
target virus was added. The virus–antibody mix was incubated at
37 °C for 2 hours, and its residual infectivity was determined using the
single-round infection assay described above. The residual infectivity
(%) was deﬁned as the infectivity measured at a given concentration
of the neutralizing agent divided by the infectivity of the same virus
stock mock-treated with cell culture medium. All experiments were
performed at least twice. Comparable results were achieved and a
typical set of results was reported. In rare cases that data variationwas
noticed between experimental sessions, the average and range of
variation from 4-repeat experiments were presented, as noted in the
ﬁgure legends.
Antibody depletion by recombinant HIV-1 Env proteins
In vitro binding/depletion assays were conducted using various
forms of recombinant HIV-1 Env proteins. Codon-optimized expres-
sion vectors were used to express the wild-type and D368R gp120monomers as well as the gp140 trimer of HIV-1JR-FL Env. The ﬁnal
products of gp120 monomers contain amino acids 31–508 with a-
GSG-linker and a 6×His tag. The soluble gp140 trimer is identical to
the gp140(−/FT) construct, as reported (Yang et al., 2002) and the
ﬁnal product contains (1) a.a. 31-683, (2) R508/511S changes to block
gp120/gp41 cleavage, (3) a -Gly-Ser-Gly-linker and the trimerization
motif of T4 bacteriophage ﬁbritin, and (4) a C-terminal 6×His tag. The
gp120 monomer and gp140 trimer were produced in 293F cells and
afﬁnity-puriﬁed using the C-terminal 6×His tag. The OD1 protein
contains amino acids 252–482 of HIV-1YU2 Env. A V3-deleted version
(OD1ΔV3) was created by deleting the following V3 sequence:
PNNNTRKSINIGPGRALYTTGEIIGDIRQ. The OD1 and OD1ΔV3 proteins
were expressed in S2 Drosophila cells and afﬁnity-puriﬁed via the C-
terminal 6×His tags, as previously reported (Yang et al., 2004).
To deplete neutralizing activities from anti-HIV-1 sera, equimolar
amounts of recombinant Env proteins (45 μg of gp140, 13.3 μg of
gp120, or 5 μg of OD1) were bound to 25 μl of Ni-NTA Superﬂow beads
(Qiagen) in 1×PBS. After 3 washes, antiserum at 2× the volume of the
quantity that caused 90% neutralization, as titrated in preliminary
experiments, was incubated with the Env/Ni-NTA complex in 400 μl
of 1×PBS at 4 °C for 1.5 hours with shaking. The unbound fractionwas
harvested and the depletion was repeated two more times. The ﬁnal
product after 3 depletions was concentrated using Centricon-100
(Amicon) and resuspended in 1×PBS to 10 volumes of the original
serum. After sterilization by passing through a 0.22-μm microﬁlter,
the residual neutralizing activity that was not depleted by the
designated Env proteins was titrated using the standard single-
round entry/neutralization assay as described above. A mock
depletionwith empty Ni-NTA beads was always conducted in parallel.V3 peptide competition assay
A peptide corresponding to the HIV-1JR-FL gp120 V3 loop,
T297RPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAH330, was custom-synthe-
sized (New England Peptides, Inc). To perform a binding/competition
assay, 10 μg/ml of the V3 peptide was mixed with an amount of
antiserum that caused 90% neutralization, as titrated by preliminary
experiments, in 1×PBS at a ﬁnal volume of 10×the original serum.
The serum/V3 peptide mixture was incubated at 4 °C for 1.5 hours,
and the residual neutralizing activity in this mixture was titrated
using the single-round entry assay described above. Mock treatments
without peptide and with the peptide only were always used in
parallel to control for speciﬁcity.Acknowledgments
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